Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oroxin A in preparation of medicines for treating cancer

A technology of phytoside and medicine, which is applied in the application field of phytoside A in the preparation of drugs for treating cancer, and can solve the problems such as no reports of phytoside A antitumor drug.

Active Publication Date: 2015-05-06
SUZHOU UNIV
View PDF4 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In the existing data, there is no report about the use of oreoside A in the preparation of antitumor drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oroxin A in preparation of medicines for treating cancer
  • Application of oroxin A in preparation of medicines for treating cancer
  • Application of oroxin A in preparation of medicines for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 In vitro experiment of oroxylin A inhibiting the proliferation of various malignant tumor cells

[0035] (1) Experimental materials

[0036] (1) Tumor cell lines (34 strains): human breast cancer cells MCF-7, human liver cancer cell lines BEL-7402, QGY-7703, HCC-8910, mouse pre-tumor stem cells 3B5C, PMKO-102-3#, p3B11 , 2C4G2, PMKO-891-5#, human chronic myelogenous leukemia cell K562, human glioma cell SHG44, human promyelocytic leukemia cell HL-60, human cervical cancer cell Hela, human osteosarcoma cell MG-63, U- 2OS, human gastric cancer cell N87, human glioma cell A172, human myeloma cell line LP-1, human melanoma high metastatic cell line A375, human monocytic leukemia cell THP-1, human adrenal neuroblastoma cell ( Brain metastasis) KP-N-NS, human colon cancer cell line SW480, human Burkitt's lymphoma cell Raji, NAMALWA, human megakaryocyte leukemia cell Dami, human ileocecal cancer cell CCL-244, mouse tumor endothelial cell 3B11 , Human cervical cancer int...

Embodiment 2

[0051] Example 2 In vitro experiment of oroxylin A inhibiting breast cancer cell proliferation

[0052] (1) Experimental materials

[0053] (1) Tumor cell line: human breast cancer cell MCF-7 is cryopreserved in our laboratory. The cell culture medium DMEM (high sugar) is a product of Hyclone.

[0054] (2) Test drug: Oriloside A (purchased from a commercial company) was dissolved with dimethyl sulfoxide (DMSO) and diluted with DMEM (high sugar) medium to the required concentration.

[0055] (2) Experimental method

[0056] Cell culture: Cells are routinely cultured with RPMI1640 or DMEM (high glucose) medium containing 10% calf serum and 1% double antibody (anti-penicillin and anti-streptomycin). Digest with 0.25% trypsin every 48-72h, and expand the flask 1:2 to 1:4 for passage.

[0057] Alamarblue method: Take the human breast cancer cell MCF-7 in the logarithmic growth phase and adjust the cell concentration to 3×10 4 / ml, seeded on 96-well cell culture plate at 100μl / well, CO 2 Con...

Embodiment 3

[0061] Example 3 In vitro experiment of oroxylin A inducing morphological changes of tumor cells

[0062] (1) Experimental materials

[0063] (1) Tumor cell line: human breast cancer cell MCF-7 is cryopreserved in our laboratory. The cell culture medium DMEM (high sugar) is a product of Hyclone.

[0064] (2) Test drug: Oriloside A (purchased from a commercial company) was dissolved with dimethyl sulfoxide (DMSO) and diluted with DMEM (high sugar) medium to the required concentration.

[0065] (2) Experimental method

[0066] Cell culture: Cells are routinely cultured with RPMI1640 or DMEM (high glucose) medium containing 10% calf serum and 1% double antibody (anti-penicillin and anti-streptomycin). Digest with 0.25% trypsin every 48-72h, and expand the flask 1:2 to 1:4 for passage.

[0067] Rui-Ji’s staining method: take human breast cancer cells in logarithmic growth phase and adjust the cell concentration to 10 4 / Well, seeded in a 24-well culture plate. After 24 hours, complete med...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to the technical field of traditional Chinese medicines, and in particular relates to an application of oroxin A in preparation of medicines for treating cancer. According to the application disclosed by the invention, research results show that oroxin A has the effect of inhibiting tumor angiogenesis, and can be used for significantly inhibiting the proliferation and growth of tumor cells, inducing the tumor cells to achieve aging heath, cycle arresting and cell apoptosis, and inhibiting the tumor cell adhesion, migration, invasion and angiogenesis; and oroxin A has very good inhibition effects on tumor growth of tumor-burdened mice.

Description

Technical field [0001] The present invention relates to the technical field of traditional Chinese medicine, in particular to the application of oriloside A in the preparation of cancer drugs. Background technique [0002] Tumor is an abnormal disease formed by the body under the action of various carcinogenic factors, and a certain cell in the local tissue loses its normal regulation of its growth at the gene level, leading to its clonal abnormal proliferation. The academic circles generally divide tumors into two categories: benign and malignant. In recent years, the incidence of malignant tumors has also increased year by year. Statistics from the Ministry of Health of the People's Republic of China show that the number of patients with malignant tumors in China currently reaches 1.15‰ to 1.27‰, and the number of deaths due to malignant tumors ranks second among all causes of death. In the past half century, although great progress has been made in the treatment of malignant...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P35/00A61P35/04A61P35/02
Inventor 周泉生曹志飞
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com